Spotlight on Emergency Medicine

Credits: 0.25 CME / MOC / CNE / CPE
Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza Postexposure Prophylaxis: Don’t Overlook the High-Risk Patient
Michael G. Ison, MD, MS
RMEI Medical Education, LLC

Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza Postexposure Prophylaxis: Don’t Overlook the High-Risk Patient

Start

Activity Details

Free CME/MOC/CNE/CPE
0.25 AMA PRA Category 1 Credit(s)
0.25 ANCC contact hour(s)
0.25 ACPE contact hour(s)
0.25 ABIM MOC point(s)
Released: October 11, 2021
Expires: October 10, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients who may be at high risk for influenza-related complications
  • Recognize the possible presentations of influenza in high-risk individuals
  • Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
  • Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza

Activity Description

In this activity, experts present a case of a high-risk patient who was exposed to influenza but did not receive antiviral chemoprophylaxis. A panel discussion highlights reasons why influenza chemoprophylaxis may be overlooked in clinical practice, as well as current guideline recommendations for who should receive it, when, and for how long. Efficacy data for antiviral therapeutic options for influenza chemoprophylaxis, including oseltamivir, zanamivir, and baloxavir marboxil, is presented.

Activity Chair

Michael G. Ison, MD, MS
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Faculty

Richard K. Zimmerman, MD, MPH, MS
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); GlaxoSmithKline (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).

Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-003-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC/CNE/CPE
0.25 AMA PRA Category 1 Credit(s)
0.25 ANCC contact hour(s)
0.25 ACPE contact hour(s)
0.25 ABIM MOC point(s)
Released: October 11, 2021
Expires: October 10, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients who may be at high risk for influenza-related complications
  • Recognize the possible presentations of influenza in high-risk individuals
  • Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
  • Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza

Activity Description

In this activity, experts present a case of a high-risk patient who was exposed to influenza but did not receive antiviral chemoprophylaxis. A panel discussion highlights reasons why influenza chemoprophylaxis may be overlooked in clinical practice, as well as current guideline recommendations for who should receive it, when, and for how long. Efficacy data for antiviral therapeutic options for influenza chemoprophylaxis, including oseltamivir, zanamivir, and baloxavir marboxil, is presented.

Activity Chair

Michael G. Ison, MD, MS
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Faculty

Richard K. Zimmerman, MD, MPH, MS
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); GlaxoSmithKline (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).

Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-003-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Emergency Medicine Presentations

1.00 CME
Vindico Medical Education
Immune-based Therapies in the Management of Patients With Severe COVID-19: What Do We Know?

Immune-based Therapies in the Management of Patients With Severe COVID-19: What Do We Know?

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: October 20, 2021
Expires: October 19, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pulmonologists, rheumatologists, hospitalists, critical care physicians, intensivists, and other health care professionals involved in the management of patients with COVID-19.

Learning Objectives

Upon successful completion of this activity, participants should be better able to: 

  • Summarize the immunopathology of COVID-19 infection as it relates to the stages of disease, with an emphasis on hyperinflammation in severe disease.
  • Assess the latest clinical evidence regarding the use of immune-based therapies in patients with severe COVID-19 infection.
  • Examine how features such as disease severity and prior treatment history may impact response to IL-6 inhibitors in patients with severe COVID-19 infection.

Activity Description

In this educational video, a multidisciplinary panel of experts will review the immunopathology underlying hyperinflammation in severe COVID-19; appraise the current evidence for immune-based therapies; and examine patient and disease characteristics that may impact response to IL-6 inhibition and other immunomodulatory therapy for severe disease.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Immune-based treatment strategies targeting the interleukin (IL)-6 and other immunomodulatory pathways have shown promise for reducing the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up-to-date on the latest evidence-based care and rapidly evolving treatment guidelines.

Agenda

Introduction and Immunopathogenesis of COVID-19 – Leonard H. Calabrese, DO
Assessing Risk for Disease Progression – Cassandra Calabrese, DO
Managing Patients With Severe COVID-19 Infection: What Do We Know? – Paul G. Auwaerter, MD, MBA, FIDSA
Case Presentations – Ivan O. Rosas, MD

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee:
AbbVie, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Pfizer, Regeneron, Sanofi-Genzyme, UCB
Speakers Bureau: AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Lilly, Regeneron, Sanofi, UCB

Faculty

Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD

Disclosure:
Ownership Interest: Johnson & Johnson


Cassandra Calabrese, DO
Assistant Professor of Medicine
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH

Disclosure:
Speakers Bureau: Sanofi-Genzyme


Ivan O. Rosas, MD
Professor and Section Chief
Pulmonary, Critical Care and Sleep Medicine
Lester and Sue Smith Chair in Lung Health
Baylor College of Medicine
Houston, TX

Disclosure:
Consulting Fee: Genentech/Roche
Contracted Research: Genentech/Roche

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: October 20, 2021
Expires: October 19, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pulmonologists, rheumatologists, hospitalists, critical care physicians, intensivists, and other health care professionals involved in the management of patients with COVID-19.

Learning Objectives

Upon successful completion of this activity, participants should be better able to: 

  • Summarize the immunopathology of COVID-19 infection as it relates to the stages of disease, with an emphasis on hyperinflammation in severe disease.
  • Assess the latest clinical evidence regarding the use of immune-based therapies in patients with severe COVID-19 infection.
  • Examine how features such as disease severity and prior treatment history may impact response to IL-6 inhibitors in patients with severe COVID-19 infection.

Activity Description

In this educational video, a multidisciplinary panel of experts will review the immunopathology underlying hyperinflammation in severe COVID-19; appraise the current evidence for immune-based therapies; and examine patient and disease characteristics that may impact response to IL-6 inhibition and other immunomodulatory therapy for severe disease.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Immune-based treatment strategies targeting the interleukin (IL)-6 and other immunomodulatory pathways have shown promise for reducing the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up-to-date on the latest evidence-based care and rapidly evolving treatment guidelines.

Agenda

Introduction and Immunopathogenesis of COVID-19 – Leonard H. Calabrese, DO
Assessing Risk for Disease Progression – Cassandra Calabrese, DO
Managing Patients With Severe COVID-19 Infection: What Do We Know? – Paul G. Auwaerter, MD, MBA, FIDSA
Case Presentations – Ivan O. Rosas, MD

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee:
AbbVie, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Pfizer, Regeneron, Sanofi-Genzyme, UCB
Speakers Bureau: AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Lilly, Regeneron, Sanofi, UCB

Faculty

Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD

Disclosure:
Ownership Interest: Johnson & Johnson


Cassandra Calabrese, DO
Assistant Professor of Medicine
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH

Disclosure:
Speakers Bureau: Sanofi-Genzyme


Ivan O. Rosas, MD
Professor and Section Chief
Pulmonary, Critical Care and Sleep Medicine
Lester and Sue Smith Chair in Lung Health
Baylor College of Medicine
Houston, TX

Disclosure:
Consulting Fee: Genentech/Roche
Contracted Research: Genentech/Roche

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.50 CME / MOC / CNE / CPE
RMEI Medical Education, LLC
Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza in High-Risk Patients: Aching for Optimal Treatment

Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza in High-Risk Patients: Aching for Optimal Treatment

Start

Activity Details

Free CME/MOC/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 ANCC contact hour(s)
0.5 ACPE contact hour(s)
0.5 ABIM MOC point(s)
Released: October 18, 2021
Expires: October 17, 2022
30 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients who may be at high risk for influenza-related complications
  • Recognize the possible presentations of influenza in high-risk individuals
  • Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
  • Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza

Activity Description

In this activity, a panel of experts discusses therapeutic options for influenza and reasons why influenza treatment is commonly overlooked even in high-risk patients. Challenges in diagnosing and treating influenza in the era of COVID-19 are highlighted. A high-risk experienced influenza patient shares her experiences with diagnosis and treatment and how influenza affected her quality of life.

Activity Chair

Michael G. Ison, MD, MS
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Faculty

Christopher J. Coyne, MD, MPH
Director, Clinical Research Department of Emergency Medicine
University of California San Diego
San Diego, CA


Richard K. Zimmerman, MD, MPH, MS
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Christopher J. Coyne, MD, MPH, has a financial relationship with Gilead Pharmaceuticals (Other: Infectious disease screening program).

Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); GlaxoSmithKline (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).

Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.5 contact hour(s) (0.5 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-004-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 ANCC contact hour(s)
0.5 ACPE contact hour(s)
0.5 ABIM MOC point(s)
Released: October 18, 2021
Expires: October 17, 2022
30 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients who may be at high risk for influenza-related complications
  • Recognize the possible presentations of influenza in high-risk individuals
  • Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
  • Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza

Activity Description

In this activity, a panel of experts discusses therapeutic options for influenza and reasons why influenza treatment is commonly overlooked even in high-risk patients. Challenges in diagnosing and treating influenza in the era of COVID-19 are highlighted. A high-risk experienced influenza patient shares her experiences with diagnosis and treatment and how influenza affected her quality of life.

Activity Chair

Michael G. Ison, MD, MS
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Faculty

Christopher J. Coyne, MD, MPH
Director, Clinical Research Department of Emergency Medicine
University of California San Diego
San Diego, CA


Richard K. Zimmerman, MD, MPH, MS
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Christopher J. Coyne, MD, MPH, has a financial relationship with Gilead Pharmaceuticals (Other: Infectious disease screening program).

Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); GlaxoSmithKline (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).

Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.5 contact hour(s) (0.5 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-004-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.25 CME / MOC / CNE / CPE
RMEI Medical Education, LLC
Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza Postexposure Prophylaxis: Don’t Overlook the High-Risk Patient

Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza Postexposure Prophylaxis: Don’t Overlook the High-Risk Patient

Start

Activity Details

Free CME/MOC/CNE/CPE
0.25 AMA PRA Category 1 Credit(s)
0.25 ANCC contact hour(s)
0.25 ACPE contact hour(s)
0.25 ABIM MOC point(s)
Released: October 11, 2021
Expires: October 10, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients who may be at high risk for influenza-related complications
  • Recognize the possible presentations of influenza in high-risk individuals
  • Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
  • Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza

Activity Description

In this activity, experts present a case of a high-risk patient who was exposed to influenza but did not receive antiviral chemoprophylaxis. A panel discussion highlights reasons why influenza chemoprophylaxis may be overlooked in clinical practice, as well as current guideline recommendations for who should receive it, when, and for how long. Efficacy data for antiviral therapeutic options for influenza chemoprophylaxis, including oseltamivir, zanamivir, and baloxavir marboxil, is presented.

Activity Chair

Michael G. Ison, MD, MS
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Faculty

Richard K. Zimmerman, MD, MPH, MS
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); GlaxoSmithKline (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).

Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-003-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC/CNE/CPE
0.25 AMA PRA Category 1 Credit(s)
0.25 ANCC contact hour(s)
0.25 ACPE contact hour(s)
0.25 ABIM MOC point(s)
Released: October 11, 2021
Expires: October 10, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients who may be at high risk for influenza-related complications
  • Recognize the possible presentations of influenza in high-risk individuals
  • Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
  • Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza

Activity Description

In this activity, experts present a case of a high-risk patient who was exposed to influenza but did not receive antiviral chemoprophylaxis. A panel discussion highlights reasons why influenza chemoprophylaxis may be overlooked in clinical practice, as well as current guideline recommendations for who should receive it, when, and for how long. Efficacy data for antiviral therapeutic options for influenza chemoprophylaxis, including oseltamivir, zanamivir, and baloxavir marboxil, is presented.

Activity Chair

Michael G. Ison, MD, MS
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Faculty

Richard K. Zimmerman, MD, MPH, MS
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); GlaxoSmithKline (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).

Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-003-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

1.00 CME
Vindico Medical Education
The Changing Landscape of Immune-Based Therapies for COVID-19

The Changing Landscape of Immune-Based Therapies for COVID-19

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: September 29, 2021
Expires: September 28, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, rheumatologists, and other health care professionals involved in the management of patients hospitalized with COVID-19 infection.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Describe the clinical and immunological events underlying the natural history of COVID-19.
  • Critically appraise the data regarding immune-based therapies for the management of hyperinflammation due to COVID-19, including glucocorticoids, Janus kinase inhibitors, and other targeted agents.
  • Describe how variables such as disease severity, timing, and immunologic endotypes should impact the management of patients hospitalized with COVID-19 infection.

Activity Description

The COVID-19 pandemic has led to a health care crisis with widespread global morbidity and mortality, spurring unprecedented levels of ongoing research for effective therapeutic strategies. A major challenge for health care providers involved in patient management is staying current on the latest evidence-based care despite the rapid influx of data. Hospitalists and other clinicians who care for hospitalized patients may rely heavily on therapies with which they are familiar, namely corticosteroids. However, immunomodulatory therapies such as Janus kinase inhibitors and interleukin-6 inhibitors provide promising options to prevent disease progression and reduce mortality risk. In this educational activity, multidisciplinary panel members review the clinical and immunological events underlying COVID-19; appraise emerging data on immunomodulatory therapies; and discuss how disease severity, timing, and immunological endotypes may impact the management of patients hospitalized with COVID-19 infection.

Agenda

Introduction and Immunopathogenesis of COVID-19
Leonard H. Calabrese, DO

Updates on Immune-Based Therapies for the Management of Patients With COVID-19
Kevin Winthrop, MD, MPH

Considerations for Outpatient Management of Immunocompromised Patients
Cassandra Calabrese, DO

Putting it All Together: How Should We Manage Patients Hospitalized With COVID-19?
D. Clark Files, MD

Conclusion
Leonard H. Calabrese, DO

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee:
AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Pfizer, Regeneron, Sanofi Genzyme, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Celgene, Genentech, Janssen, Lilly, Regeneron, Sanofi, UCB

Faculty

Cassandra Calabrese, DO
Assistant Professor of Medicine
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH

Disclosure:
Speakers Bureau: Sanofi-Genzyme


D. Clark Files, MD
Associate Professor
Pulmonary, Critical Care, Allergy, and Immunologic Diseases
Wake Forest School of Medicine
Winston-Salem, NC

Disclosure:
Consulting Fee: California Institute of Regenerative Medicine
Data Safety Monitoring Board: Medpace


Kevin Winthrop, MD, MPH
Professor, Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Sciences University
Portland, OR

Disclosure:
Consulting Fee: Horizon, Insmed, Paratek, Red Hill Biopharma, Spero
Contracted Research: Insmed

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: September 29, 2021
Expires: September 28, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, rheumatologists, and other health care professionals involved in the management of patients hospitalized with COVID-19 infection.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Describe the clinical and immunological events underlying the natural history of COVID-19.
  • Critically appraise the data regarding immune-based therapies for the management of hyperinflammation due to COVID-19, including glucocorticoids, Janus kinase inhibitors, and other targeted agents.
  • Describe how variables such as disease severity, timing, and immunologic endotypes should impact the management of patients hospitalized with COVID-19 infection.

Activity Description

The COVID-19 pandemic has led to a health care crisis with widespread global morbidity and mortality, spurring unprecedented levels of ongoing research for effective therapeutic strategies. A major challenge for health care providers involved in patient management is staying current on the latest evidence-based care despite the rapid influx of data. Hospitalists and other clinicians who care for hospitalized patients may rely heavily on therapies with which they are familiar, namely corticosteroids. However, immunomodulatory therapies such as Janus kinase inhibitors and interleukin-6 inhibitors provide promising options to prevent disease progression and reduce mortality risk. In this educational activity, multidisciplinary panel members review the clinical and immunological events underlying COVID-19; appraise emerging data on immunomodulatory therapies; and discuss how disease severity, timing, and immunological endotypes may impact the management of patients hospitalized with COVID-19 infection.

Agenda

Introduction and Immunopathogenesis of COVID-19
Leonard H. Calabrese, DO

Updates on Immune-Based Therapies for the Management of Patients With COVID-19
Kevin Winthrop, MD, MPH

Considerations for Outpatient Management of Immunocompromised Patients
Cassandra Calabrese, DO

Putting it All Together: How Should We Manage Patients Hospitalized With COVID-19?
D. Clark Files, MD

Conclusion
Leonard H. Calabrese, DO

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee:
AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Pfizer, Regeneron, Sanofi Genzyme, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Celgene, Genentech, Janssen, Lilly, Regeneron, Sanofi, UCB

Faculty

Cassandra Calabrese, DO
Assistant Professor of Medicine
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH

Disclosure:
Speakers Bureau: Sanofi-Genzyme


D. Clark Files, MD
Associate Professor
Pulmonary, Critical Care, Allergy, and Immunologic Diseases
Wake Forest School of Medicine
Winston-Salem, NC

Disclosure:
Consulting Fee: California Institute of Regenerative Medicine
Data Safety Monitoring Board: Medpace


Kevin Winthrop, MD, MPH
Professor, Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Sciences University
Portland, OR

Disclosure:
Consulting Fee: Horizon, Insmed, Paratek, Red Hill Biopharma, Spero
Contracted Research: Insmed

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.00 CME / CNE / CPE
AcademicCME
Advances in Patient-Controlled On-Demand Treatment of Paroxysmal Supraventricular Tachycardia

Advances in Patient-Controlled On-Demand Treatment of Paroxysmal Supraventricular Tachycardia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 CNE Contact Hour(s)
1.0 CPE Contact Hour(s) (CEUs)
Released: June 3, 2021
Expires: June 2, 2022
60 minutes to complete

Accredited By

Target Audience

The target audience includes interventional and clinical cardiologists, cardiothoracic and trauma surgeons, and emergency medicine/critical care specialists, as well as other clinicians who manage patients with PSVT.

Learning Objectives

  1. Review the symptom burden, epidemiologic, and pharmacoeconomic basis of current abortive strategies for PSVT
  2. Analyze and understand the different perspectives of various healthcare providers on optimizing PSVT management
  3. Discuss workflow, collaboration, and management strategies for clinical trial execution in the current pandemic-impacted era of practice
  4. Review in detail the rationale and methodology of a Phase 3 clinical trial that identifies patients with PSVT suitable for patient-actuated treatment, and follow its execution as the scientific, clinical, and outcomes-driven environment of PSVT management evolves

Activity Description

Unpredictable episodes of paroxysmal supraventricular tachycardia (PSVT) often have a negative impact on patient quality of life by causing uncomfortable, disconcerting symptoms during episodes (e.g., palpitations, chest pain, dizziness, syncope, shortness of breath, anxiety), by imposing restrictions on patient activities, and by potential association with medication-related side effects. Among commercially insured patients, healthcare spending increases substantially following diagnosis of PSVT, and more than two-thirds of that increased spending is for services related to PSVT and other cardiac rhythm disorders. These spending increases are seen for both outpatient and inpatient services; in particular, emergency department (ED) visits and hospitalizations both increase in the year following diagnosis, and then look-back analysis typically confirms that ED utilization is also high in the year prior to diagnosis, potentially reflecting difficulties with diagnosis. Current treatment approaches for PSVT are associated with a large burden on providers and carry a high economic burden for payers; just as importantly, however, they create a sense of powerlessness among many patients that often cannot be addressed with a reliable self-treatment strategy. New approaches are warranted to improve diagnosis, management, quality of life, and sense of well-being among patients with PSVT.

AcademicCME has developed a 1-hour program addressing the epidemiology, disease burden, definitive diagnosis, and current therapy of acute episodes of PSVT, along with information about an ongoing phase 3 trial that will evaluate the safety and efficacy of an on-demand, patient-actuated treatment for PSVT.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with paroxysmal supraventricular tachycardia (PSVT).

Agenda

  1. PSVT: Disease Burden
  2. Clinical Perspectives on Current and Emerging Pharmacologic Therapies for PSVT
    1. The NODE-301 and RAPID Phase 3 Trials
  3. Rationale and Methodology of a Phase 3 Placebo-Controlled Trial of a New, Patient-Actuated Therapy for PSVT
  4. Challenges in Executing Clinical Trials in the Acute Care Environment During COVID
  5. Expert Panel Discussion

Faculty

Paul Dorian, MD
Professor of Medicine and Pharmacology
University of Toronto
St Michael’s Hospital
Toronto, Ontario, Canada


Charles V. Pollack Jr., MA, MD
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


Bruce Stambler, MD
Cardiology and Electrophysiology
Piedmont Heart Institute
Atlanta, Georgia

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack Jr., MA, MD (Course Chair)
Consultant/Advisor: AstraZeneca Pharmaceuticals; PhaseBio Pharmaceuticals, Inc.; Milestone Pharmaceuticals, Inc.
Grant/Research Support: AstraZeneca Pharmaceuticals

Paul Dorian, MD
Consultant/Advisor: Milestone Pharmaceuticals, Inc.

Bruce Stambler, MD
Consultant/Advisor: Milestone Pharmaceuticals, Inc.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Through an agreement between the American Medical Association and the European Union of Medical Specialists, physicians may convert AMA PRA Category 1 Credit(s)™ to an equivalent number of European CME Credits® (ECMECs®). These credits will be recognized by all National Accreditation Authorities in Europe with which the UEMS has a signed agreement of recognition of credits.

The Royal College and Physicians and Surgeons of Canada recognizes credits offered by the ACCME through the International Academy for CPD Accreditation agreement.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour (Provider Number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (UAN #: JA4008190-0000-21-013-H04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
    • CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    • CME and CNE credit will be issued appropriate certificate of completion.
    • Others may request a "certificate of completion".
  5. Learners who receive a grade of 60% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  6. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from Milestone Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Milestone Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 CNE Contact Hour(s)
1.0 CPE Contact Hour(s) (CEUs)
Released: June 3, 2021
Expires: June 2, 2022
60 minutes to complete

Accredited By

Target Audience

The target audience includes interventional and clinical cardiologists, cardiothoracic and trauma surgeons, and emergency medicine/critical care specialists, as well as other clinicians who manage patients with PSVT.

Learning Objectives

  1. Review the symptom burden, epidemiologic, and pharmacoeconomic basis of current abortive strategies for PSVT
  2. Analyze and understand the different perspectives of various healthcare providers on optimizing PSVT management
  3. Discuss workflow, collaboration, and management strategies for clinical trial execution in the current pandemic-impacted era of practice
  4. Review in detail the rationale and methodology of a Phase 3 clinical trial that identifies patients with PSVT suitable for patient-actuated treatment, and follow its execution as the scientific, clinical, and outcomes-driven environment of PSVT management evolves

Activity Description

Unpredictable episodes of paroxysmal supraventricular tachycardia (PSVT) often have a negative impact on patient quality of life by causing uncomfortable, disconcerting symptoms during episodes (e.g., palpitations, chest pain, dizziness, syncope, shortness of breath, anxiety), by imposing restrictions on patient activities, and by potential association with medication-related side effects. Among commercially insured patients, healthcare spending increases substantially following diagnosis of PSVT, and more than two-thirds of that increased spending is for services related to PSVT and other cardiac rhythm disorders. These spending increases are seen for both outpatient and inpatient services; in particular, emergency department (ED) visits and hospitalizations both increase in the year following diagnosis, and then look-back analysis typically confirms that ED utilization is also high in the year prior to diagnosis, potentially reflecting difficulties with diagnosis. Current treatment approaches for PSVT are associated with a large burden on providers and carry a high economic burden for payers; just as importantly, however, they create a sense of powerlessness among many patients that often cannot be addressed with a reliable self-treatment strategy. New approaches are warranted to improve diagnosis, management, quality of life, and sense of well-being among patients with PSVT.

AcademicCME has developed a 1-hour program addressing the epidemiology, disease burden, definitive diagnosis, and current therapy of acute episodes of PSVT, along with information about an ongoing phase 3 trial that will evaluate the safety and efficacy of an on-demand, patient-actuated treatment for PSVT.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with paroxysmal supraventricular tachycardia (PSVT).

Agenda

  1. PSVT: Disease Burden
  2. Clinical Perspectives on Current and Emerging Pharmacologic Therapies for PSVT
    1. The NODE-301 and RAPID Phase 3 Trials
  3. Rationale and Methodology of a Phase 3 Placebo-Controlled Trial of a New, Patient-Actuated Therapy for PSVT
  4. Challenges in Executing Clinical Trials in the Acute Care Environment During COVID
  5. Expert Panel Discussion

Faculty

Paul Dorian, MD
Professor of Medicine and Pharmacology
University of Toronto
St Michael’s Hospital
Toronto, Ontario, Canada


Charles V. Pollack Jr., MA, MD
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


Bruce Stambler, MD
Cardiology and Electrophysiology
Piedmont Heart Institute
Atlanta, Georgia

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack Jr., MA, MD (Course Chair)
Consultant/Advisor: AstraZeneca Pharmaceuticals; PhaseBio Pharmaceuticals, Inc.; Milestone Pharmaceuticals, Inc.
Grant/Research Support: AstraZeneca Pharmaceuticals

Paul Dorian, MD
Consultant/Advisor: Milestone Pharmaceuticals, Inc.

Bruce Stambler, MD
Consultant/Advisor: Milestone Pharmaceuticals, Inc.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Through an agreement between the American Medical Association and the European Union of Medical Specialists, physicians may convert AMA PRA Category 1 Credit(s)™ to an equivalent number of European CME Credits® (ECMECs®). These credits will be recognized by all National Accreditation Authorities in Europe with which the UEMS has a signed agreement of recognition of credits.

The Royal College and Physicians and Surgeons of Canada recognizes credits offered by the ACCME through the International Academy for CPD Accreditation agreement.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour (Provider Number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (UAN #: JA4008190-0000-21-013-H04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
    • CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    • CME and CNE credit will be issued appropriate certificate of completion.
    • Others may request a "certificate of completion".
  5. Learners who receive a grade of 60% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  6. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from Milestone Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Milestone Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

0.75 CME / CNE / CPE
Global Education Group
HIV Experts & Evidence™: A Two-Part Continuing Medical Education Series on the Evolving Models of HIV Care – Part 1: Rapid ART Initiation: A Key Strategy for Ending the HIV Epidemic

HIV Experts & Evidence™: A Two-Part Continuing Medical Education Series on the Evolving Models of HIV Care – Part 1: Rapid ART Initiation: A Key Strategy for Ending the HIV Epidemic

Start

Activity Details

Free CME/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 Contact Hour(s)
Released: May 4, 2021
Expires: May 4, 2022
45 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

This activity is intended for infectious diseases and human immunodeficiency virus (HIV)-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objectives

  • Reduce time from HIV diagnosis to viral suppression to improve patient outcomes and prevent HIV transmission
  • Select appropriate regimens for rapid ART initiation based on current guidelines and patient characteristics
  • Implement strategies designed to decrease barriers to the provision of rapid ART to patients with newly diagnosed HIV infection

Activity Description

In Part 1, we introduce the central role rapid ART initiation can play in ending the HIV epidemic. This strategy has demonstrated increased immediate ART uptake and decreased time to viral suppression and holds hope for reducing HIV transmission risk, community viral load, and inequities in ART access. Part 1 will present programs that model successful rapid-ART implementation within different care-delivery systems and patient populations.

Statement of Educational Need

Guideline-based rapid initiation of antiretroviral therapy (ART) for treatment of HIV is now the standard of care.1 Best-practice rapid ART protocols promote immediate linkage to HIV care, decreased time to ART initiation, decreased time to viral suppression (VS), and long-term VS—even within vulnerable populations.2 Shorter time to VS is associated with decreases in the incidence of both AIDS- and non-AIDS–related events.3 It further benefits the individual’s partners and at-risk populations by decreasing the period of time during which the virus is transmittable. This informs the Undetectable Equals Untransmittable (U=U) initiative, which serves not only the public health goal of ending the HIV/AIDS pandemic, but also brings equity to HIV care for vulnerable populations.4 Geared to the needs of HIV-specialist clinicians, this two-part HIV Experts and Evidence™ enduring activity will address rapid ART guidelines, provide practical solutions to systemic and clinical barriers that can impede access to rapid ART regimens and retention in care, and real-world approaches to enhanced patient-centered services.

References

  1. U.S. Department of Health and Human Services. Guidelines for Use of Antiretroviral Agents in HIV-1−Infected Adults and Adolescents Living with HIV. Last updated July 2020. https://aidsinfo.nih.gov/guidelines. Accessed August 24, 2020.
  2. Coffey S, et al. RAPID antiretroviral therapy: high virologic suppression rates with immediate ART initiation in a vulnerable urban clinic population AIDS. 2019;33(5):825-832.
  3. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.
  4. Eisinger RW, et al. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. JAMA. 2019;321(5):451-452.

Faculty

Jonathan A. Colasanti, MD, MSPH
Associate Professor of Medicine
Emory University School of Medicine
Medical Director, Infectious Diseases Program
Grady Health System
Atlanta, Georgia


Jason Halperin, MD, MPH
Assistant Professor of Medicine
Tulane University School of Medicine
HIV/ID Clinician Lead, CrescentCare
New Orleans, Louisiana

Disclosure of Conflicts of Interest

Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Jonathan A. Colasanti, MD, MSPH - Nothing to disclose
Jason Halperin, MD, MPH - Nothing to disclose

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Jeanette Ruby, MD - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Global is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.75 contact hour(s) is provided by Global. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Accreditation Council for Pharmacy EducationGlobal is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


Credit Designation
Global designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-20-184-H02-P).

This is a knowledge-based activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 75% or better on the posttest and complete the program evaluation. For ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Activity Details

Free CME/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 Contact Hour(s)
Released: May 4, 2021
Expires: May 4, 2022
45 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

This activity is intended for infectious diseases and human immunodeficiency virus (HIV)-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objectives

  • Reduce time from HIV diagnosis to viral suppression to improve patient outcomes and prevent HIV transmission
  • Select appropriate regimens for rapid ART initiation based on current guidelines and patient characteristics
  • Implement strategies designed to decrease barriers to the provision of rapid ART to patients with newly diagnosed HIV infection

Activity Description

In Part 1, we introduce the central role rapid ART initiation can play in ending the HIV epidemic. This strategy has demonstrated increased immediate ART uptake and decreased time to viral suppression and holds hope for reducing HIV transmission risk, community viral load, and inequities in ART access. Part 1 will present programs that model successful rapid-ART implementation within different care-delivery systems and patient populations.

Statement of Educational Need

Guideline-based rapid initiation of antiretroviral therapy (ART) for treatment of HIV is now the standard of care.1 Best-practice rapid ART protocols promote immediate linkage to HIV care, decreased time to ART initiation, decreased time to viral suppression (VS), and long-term VS—even within vulnerable populations.2 Shorter time to VS is associated with decreases in the incidence of both AIDS- and non-AIDS–related events.3 It further benefits the individual’s partners and at-risk populations by decreasing the period of time during which the virus is transmittable. This informs the Undetectable Equals Untransmittable (U=U) initiative, which serves not only the public health goal of ending the HIV/AIDS pandemic, but also brings equity to HIV care for vulnerable populations.4 Geared to the needs of HIV-specialist clinicians, this two-part HIV Experts and Evidence™ enduring activity will address rapid ART guidelines, provide practical solutions to systemic and clinical barriers that can impede access to rapid ART regimens and retention in care, and real-world approaches to enhanced patient-centered services.

References

  1. U.S. Department of Health and Human Services. Guidelines for Use of Antiretroviral Agents in HIV-1−Infected Adults and Adolescents Living with HIV. Last updated July 2020. https://aidsinfo.nih.gov/guidelines. Accessed August 24, 2020.
  2. Coffey S, et al. RAPID antiretroviral therapy: high virologic suppression rates with immediate ART initiation in a vulnerable urban clinic population AIDS. 2019;33(5):825-832.
  3. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.
  4. Eisinger RW, et al. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. JAMA. 2019;321(5):451-452.

Faculty

Jonathan A. Colasanti, MD, MSPH
Associate Professor of Medicine
Emory University School of Medicine
Medical Director, Infectious Diseases Program
Grady Health System
Atlanta, Georgia


Jason Halperin, MD, MPH
Assistant Professor of Medicine
Tulane University School of Medicine
HIV/ID Clinician Lead, CrescentCare
New Orleans, Louisiana

Disclosure of Conflicts of Interest

Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Jonathan A. Colasanti, MD, MSPH - Nothing to disclose
Jason Halperin, MD, MPH - Nothing to disclose

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Jeanette Ruby, MD - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Global is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.75 contact hour(s) is provided by Global. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Accreditation Council for Pharmacy EducationGlobal is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


Credit Designation
Global designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-20-184-H02-P).

This is a knowledge-based activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 75% or better on the posttest and complete the program evaluation. For ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

0.75 CME / CNE / CPE
Global Education Group
HIV Experts & Evidence™: A Two-Part Continuing Medical Education Series on the Evolving Models of HIV Care – Part 2: Overcoming Barriers: Successful Rapid ART Initiation

HIV Experts & Evidence™: A Two-Part Continuing Medical Education Series on the Evolving Models of HIV Care – Part 2: Overcoming Barriers: Successful Rapid ART Initiation

Start

Activity Details

Free CME/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 Contact Hour(s)
Released: May 4, 2021
Expires: May 4, 2022
45 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

This activity is intended for infectious diseases and human immunodeficiency virus (HIV)-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objectives

  • Reduce time from HIV diagnosis to viral suppression to improve patient outcomes and prevent HIV transmission
  • Select appropriate regimens for rapid ART initiation based on current guidelines and patient characteristics
  • Implement strategies designed to decrease barriers to the provision of rapid ART to patients with newly diagnosed HIV infection

Activity Description

In Part 2, we will address common real-world barriers to rapid-ART implementation at the levels of systems, clinics, providers, and patients. We will then review guideline-based antiretroviral selection in the Rapid ART context and show how you can move beyond perceived barriers to quickly and safely initiate ART and achieve viral suppression.

Statement of Educational Need

Guideline-based rapid initiation of antiretroviral therapy (ART) for treatment of HIV is now the standard of care.1 Best-practice rapid ART protocols promote immediate linkage to HIV care, decreased time to ART initiation, decreased time to viral suppression (VS), and long-term VS—even within vulnerable populations.2 Shorter time to VS is associated with decreases in the incidence of both AIDS- and non-AIDS–related events.3 It further benefits the individual’s partners and at-risk populations by decreasing the period of time during which the virus is transmittable. This informs the Undetectable Equals Untransmittable (U=U) initiative, which serves not only the public health goal of ending the HIV/AIDS pandemic, but also brings equity to HIV care for vulnerable populations.4 Geared to the needs of HIV-specialist clinicians, this two-part HIV Experts and Evidence™ enduring activity will address rapid ART guidelines, provide practical solutions to systemic and clinical barriers that can impede access to rapid ART regimens and retention in care, and real-world approaches to enhanced patient-centered services.

References

  1. U.S. Department of Health and Human Services. Guidelines for Use of Antiretroviral Agents in HIV-1−Infected Adults and Adolescents Living with HIV. Last updated July 2020. https://aidsinfo.nih.gov/guidelines. Accessed August 24, 2020.
  2. Coffey S, et al. RAPID antiretroviral therapy: high virologic suppression rates with immediate ART initiation in a vulnerable urban clinic population AIDS. 2019;33(5):825-832.
  3. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.
  4. Eisinger RW, et al. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. JAMA. 2019;321(5):451-452.

Faculty

Jonathan A. Colasanti, MD, MSPH
Associate Professor of Medicine
Emory University School of Medicine
Medical Director, Infectious Diseases Program
Grady Health System
Atlanta, Georgia


Jason Halperin, MD, MPH
Assistant Professor of Medicine
Tulane University School of Medicine
HIV/ID Clinician Lead, CrescentCare
New Orleans, Louisiana

Disclosure of Conflicts of Interest

Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Jonathan A. Colasanti, MD, MSPH - Nothing to disclose
Jason Halperin, MD, MPH - Nothing to disclose

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Jeanette Ruby, MD - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Global is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.75 contact hour(s) is provided by Global. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Accreditation Council for Pharmacy EducationGlobal is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


Credit Designation
Global designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-21-051-H02-P).

This is a knowledge-based activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 75% or better on the posttest and complete the program evaluation. For ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Activity Details

Free CME/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 Contact Hour(s)
Released: May 4, 2021
Expires: May 4, 2022
45 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

This activity is intended for infectious diseases and human immunodeficiency virus (HIV)-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objectives

  • Reduce time from HIV diagnosis to viral suppression to improve patient outcomes and prevent HIV transmission
  • Select appropriate regimens for rapid ART initiation based on current guidelines and patient characteristics
  • Implement strategies designed to decrease barriers to the provision of rapid ART to patients with newly diagnosed HIV infection

Activity Description

In Part 2, we will address common real-world barriers to rapid-ART implementation at the levels of systems, clinics, providers, and patients. We will then review guideline-based antiretroviral selection in the Rapid ART context and show how you can move beyond perceived barriers to quickly and safely initiate ART and achieve viral suppression.

Statement of Educational Need

Guideline-based rapid initiation of antiretroviral therapy (ART) for treatment of HIV is now the standard of care.1 Best-practice rapid ART protocols promote immediate linkage to HIV care, decreased time to ART initiation, decreased time to viral suppression (VS), and long-term VS—even within vulnerable populations.2 Shorter time to VS is associated with decreases in the incidence of both AIDS- and non-AIDS–related events.3 It further benefits the individual’s partners and at-risk populations by decreasing the period of time during which the virus is transmittable. This informs the Undetectable Equals Untransmittable (U=U) initiative, which serves not only the public health goal of ending the HIV/AIDS pandemic, but also brings equity to HIV care for vulnerable populations.4 Geared to the needs of HIV-specialist clinicians, this two-part HIV Experts and Evidence™ enduring activity will address rapid ART guidelines, provide practical solutions to systemic and clinical barriers that can impede access to rapid ART regimens and retention in care, and real-world approaches to enhanced patient-centered services.

References

  1. U.S. Department of Health and Human Services. Guidelines for Use of Antiretroviral Agents in HIV-1−Infected Adults and Adolescents Living with HIV. Last updated July 2020. https://aidsinfo.nih.gov/guidelines. Accessed August 24, 2020.
  2. Coffey S, et al. RAPID antiretroviral therapy: high virologic suppression rates with immediate ART initiation in a vulnerable urban clinic population AIDS. 2019;33(5):825-832.
  3. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.
  4. Eisinger RW, et al. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. JAMA. 2019;321(5):451-452.

Faculty

Jonathan A. Colasanti, MD, MSPH
Associate Professor of Medicine
Emory University School of Medicine
Medical Director, Infectious Diseases Program
Grady Health System
Atlanta, Georgia


Jason Halperin, MD, MPH
Assistant Professor of Medicine
Tulane University School of Medicine
HIV/ID Clinician Lead, CrescentCare
New Orleans, Louisiana

Disclosure of Conflicts of Interest

Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Jonathan A. Colasanti, MD, MSPH - Nothing to disclose
Jason Halperin, MD, MPH - Nothing to disclose

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Jeanette Ruby, MD - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Global is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.75 contact hour(s) is provided by Global. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Accreditation Council for Pharmacy EducationGlobal is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


Credit Designation
Global designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-21-051-H02-P).

This is a knowledge-based activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 75% or better on the posttest and complete the program evaluation. For ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

1.00 CME / MOC
AKH Inc., Advancing Knowledge in Healthcare
Real-World Antimicrobial Data in Clinical Practice: Broadening Coverage at the Bedside: A Clinical Forum℠

Real-World Antimicrobial Data in Clinical Practice: Broadening Coverage at the Bedside: A Clinical Forum℠

Start

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)™/ABIM MOC point(s)
Released: December 30, 2020
Expires: December 29, 2021
60 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

This activity is designed for infectious disease, critical care, and primary care clinicians.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe the importance of real-world evidence in clinical decision-making for antimicrobial selection
  • Evaluate real-world data (RWD) as it relates to off-label indications and novel endpoints for gram-positive antimicrobials
  • Apply RWD to ascertain the benefit of antibiotics against a wide spectrum of multidrug-resistant gram-negative bacterial infections

Activity Description

During this activity, Drs. Lodise, Reilly, and Jorgensen present the importance of applying real-world data for antimicrobials in clinical practice. Faculty review highlights from recent real-world evidence and clinical observations for oritavancin, ceftaroline, telavancin, meropenem-vaborbactam, and ceftazidime-avibactam.

Statement of Educational Need

Real-world studies (RWS) are an important means by which data from randomized clinical trials (RCTs) is validated in many different clinical settings. Real-world evidence provides key information on long-term outcomes, efficacy, and safety by gathering prospective or retrospective data from diverse patient populations. RCTs for antimicrobials are limited by strict inclusion and exclusion criteria which lowers patient acuity versus that seen in clinical practice, exclusion of patients at risk for adverse safety outcomes, and challenges in gaining consent from critically ill patients. In addition to evaluating various dosing regimens and providing a wide range of outcomes over time, RWS for antimicrobials include patients who are underrepresented in RCTs and those with resistant infections and higher disease severity. Data obtained from RWS can assist clinicians with therapeutic decision-making for their patients with serious bacterial infections.

Faculty

Chair
Thomas Lodise, PharmD, PhD
Professor
Department of Pharmacy 
Albany College of Pharmacy and Health Services 
Albany, NY 


Joseph Reilly, BS, PharmD, BCGP
Director, Residency Program
Clinical Pharmacist Specialist, Infectious Diseases
AtlantiCare Regional Medical Center
Egg Harbor Township, NJ


Sarah Jorgensen, PharmD, MPH, BCPS, BCIDP, AAHIVP
Pharmacotherapy Specialist
Department of Pharmacy
Mount Sinai Hospital
Toronto, ON, Canada


Disclosure Declaration

It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of, or combination of, the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc. planners and reviewers have no relevant financial relationships to disclose.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

Thomas Lodise, PharmD, PhD, has affiliations with:
Melinta, Merck, Shionogi Inc. (Consultant); Melinta, Shionogi Inc. (Speakers Bureau)

Joseph Reilly, BS, PharmD, BCGP, has affiliations with:
Cumberland, Melinta (Speakers Bureau)

Sarah Jorgensen, PharmD, MPH, BCPS, BCIDP, AAHIVP, has affiliations with:
Sunovion (Speakers Bureau)

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations, has no financial relationships to disclose.

RMEI Medical Education, LLC
Sherri Kramer, MD, Senior Medical Director, has no financial relationships to disclose.
Sharon Powell, Editor, has no financial relationships to disclose.
The RMEI Medical Education planners and managers have nothing to disclose.

Accreditation Statement

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points and 0 patient safety credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Statements of credit will be awarded based on the participant reviewing the presentation, scoring a 70% on the post-test, and completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. There is no fee to participant in this activity. If you have questions about this CME activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations

This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Melinta Therapeutics, Inc.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Contact Information for Questions About the Activity

Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)™/ABIM MOC point(s)
Released: December 30, 2020
Expires: December 29, 2021
60 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

This activity is designed for infectious disease, critical care, and primary care clinicians.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe the importance of real-world evidence in clinical decision-making for antimicrobial selection
  • Evaluate real-world data (RWD) as it relates to off-label indications and novel endpoints for gram-positive antimicrobials
  • Apply RWD to ascertain the benefit of antibiotics against a wide spectrum of multidrug-resistant gram-negative bacterial infections

Activity Description

During this activity, Drs. Lodise, Reilly, and Jorgensen present the importance of applying real-world data for antimicrobials in clinical practice. Faculty review highlights from recent real-world evidence and clinical observations for oritavancin, ceftaroline, telavancin, meropenem-vaborbactam, and ceftazidime-avibactam.

Statement of Educational Need

Real-world studies (RWS) are an important means by which data from randomized clinical trials (RCTs) is validated in many different clinical settings. Real-world evidence provides key information on long-term outcomes, efficacy, and safety by gathering prospective or retrospective data from diverse patient populations. RCTs for antimicrobials are limited by strict inclusion and exclusion criteria which lowers patient acuity versus that seen in clinical practice, exclusion of patients at risk for adverse safety outcomes, and challenges in gaining consent from critically ill patients. In addition to evaluating various dosing regimens and providing a wide range of outcomes over time, RWS for antimicrobials include patients who are underrepresented in RCTs and those with resistant infections and higher disease severity. Data obtained from RWS can assist clinicians with therapeutic decision-making for their patients with serious bacterial infections.

Faculty

Chair
Thomas Lodise, PharmD, PhD
Professor
Department of Pharmacy 
Albany College of Pharmacy and Health Services 
Albany, NY 


Joseph Reilly, BS, PharmD, BCGP
Director, Residency Program
Clinical Pharmacist Specialist, Infectious Diseases
AtlantiCare Regional Medical Center
Egg Harbor Township, NJ


Sarah Jorgensen, PharmD, MPH, BCPS, BCIDP, AAHIVP
Pharmacotherapy Specialist
Department of Pharmacy
Mount Sinai Hospital
Toronto, ON, Canada


Disclosure Declaration

It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of, or combination of, the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc. planners and reviewers have no relevant financial relationships to disclose.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

Thomas Lodise, PharmD, PhD, has affiliations with:
Melinta, Merck, Shionogi Inc. (Consultant); Melinta, Shionogi Inc. (Speakers Bureau)

Joseph Reilly, BS, PharmD, BCGP, has affiliations with:
Cumberland, Melinta (Speakers Bureau)

Sarah Jorgensen, PharmD, MPH, BCPS, BCIDP, AAHIVP, has affiliations with:
Sunovion (Speakers Bureau)

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations, has no financial relationships to disclose.

RMEI Medical Education, LLC
Sherri Kramer, MD, Senior Medical Director, has no financial relationships to disclose.
Sharon Powell, Editor, has no financial relationships to disclose.
The RMEI Medical Education planners and managers have nothing to disclose.

Accreditation Statement

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points and 0 patient safety credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Statements of credit will be awarded based on the participant reviewing the presentation, scoring a 70% on the post-test, and completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. There is no fee to participant in this activity. If you have questions about this CME activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations

This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Melinta Therapeutics, Inc.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Contact Information for Questions About the Activity

Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.

0.50 CME
The France Foundation
Diagnosis of Thrombotic Thrombocytopenic Purpura (TTP)

Diagnosis of Thrombotic Thrombocytopenic Purpura (TTP)

Start

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: December 14, 2020
Expires: December 13, 2021
30 minutes to complete

Accredited By

Target Audience

This activity is intended for hematologists, emergency medicine physicians, critical care physicians, and primary care providers.

Learning Objectives

Upon completion of this course, the participants should be able to:

  • Differentiate acquired TTP from hereditary TTP
  • Recognize cardinal features in the presentation of TTP
  • Diagnose TTP accurately using recommended tests
  • Distinguish between TTP and other disorders in a differential diagnosis

Statement of Educational Need

Given the recent updates in research, progress in diagnosis and treatment, and the rarity of TTP and its associated 90%+ mortality rate if untreated, it is imperative that physicians become conversant with the disorder and the new information associated with its recognition, diagnosis, and treatment.

Faculty

Katerina Pavenski, MD, FRCPC
Head, Division of Transfusion Medicine
St. Michael’s Hospital
University of Toronto
Toronto, Canada

Katerina Pavenski, MD, FRCPC, has served as a consultant for Alexion, Sanofi, and Takeda. She has received contract research support from Sanofi.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, TFF and the ISTH require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and the ISTH resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and the ISTH seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and the ISTH are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation (TFF) and the International Society on Thrombosis and Haemostasis (ISTH). TFF is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Physicians
TFF designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by TFF, an ACCME-accredited provider.

Instructions for Receiving Credit

  1. Review the activity objectives and CME/CE information.
  2. Complete the CME/CE activity.
  3. Complete the online posttest. A score of 100% is required to complete this activity. The participant may take the test until successfully passed.
  4. Complete the CME/CE evaluation/attestation form. This form provides each participant the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  5. Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.

Statement of Commercial Support

This activity is supported by educational grants from Shire and Sanofi Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF and the ISTH present this information for educational purposes only. The content is provided solely by faculty who have been selected for their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. TFF, the ISTH, and the commercial supporter(s) assume no liability for the information herein.

TFF and the ISTH require CME faculty (speakers) to disclose when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational. This includes any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration-approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and the ISTH do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: December 14, 2020
Expires: December 13, 2021
30 minutes to complete

Accredited By

Target Audience

This activity is intended for hematologists, emergency medicine physicians, critical care physicians, and primary care providers.

Learning Objectives

Upon completion of this course, the participants should be able to:

  • Differentiate acquired TTP from hereditary TTP
  • Recognize cardinal features in the presentation of TTP
  • Diagnose TTP accurately using recommended tests
  • Distinguish between TTP and other disorders in a differential diagnosis

Statement of Educational Need

Given the recent updates in research, progress in diagnosis and treatment, and the rarity of TTP and its associated 90%+ mortality rate if untreated, it is imperative that physicians become conversant with the disorder and the new information associated with its recognition, diagnosis, and treatment.

Faculty

Katerina Pavenski, MD, FRCPC
Head, Division of Transfusion Medicine
St. Michael’s Hospital
University of Toronto
Toronto, Canada

Katerina Pavenski, MD, FRCPC, has served as a consultant for Alexion, Sanofi, and Takeda. She has received contract research support from Sanofi.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, TFF and the ISTH require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and the ISTH resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and the ISTH seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and the ISTH are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation (TFF) and the International Society on Thrombosis and Haemostasis (ISTH). TFF is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Physicians
TFF designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by TFF, an ACCME-accredited provider.

Instructions for Receiving Credit

  1. Review the activity objectives and CME/CE information.
  2. Complete the CME/CE activity.
  3. Complete the online posttest. A score of 100% is required to complete this activity. The participant may take the test until successfully passed.
  4. Complete the CME/CE evaluation/attestation form. This form provides each participant the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  5. Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.

Statement of Commercial Support

This activity is supported by educational grants from Shire and Sanofi Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF and the ISTH present this information for educational purposes only. The content is provided solely by faculty who have been selected for their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. TFF, the ISTH, and the commercial supporter(s) assume no liability for the information herein.

TFF and the ISTH require CME faculty (speakers) to disclose when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational. This includes any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration-approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and the ISTH do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

1.00 CME / CNE / CPE
AcademicCME
Managing Hemorrhagic Complications and Bleeding Risks Associated with Platelet P2Y12 Inhibitor Therapy

Managing Hemorrhagic Complications and Bleeding Risks Associated with Platelet P2Y12 Inhibitor Therapy

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: December 2, 2020
Expires: December 1, 2021
60 minutes to complete

Accredited By

Target Audience

Interventional and clinical cardiologists, cardiothoracic and trauma surgeons, and emergency medicine/critical care specialists, as well as other clinicians, including nurses, NPs, PAs, and pharmacists who manage patients with P2Y12 inhibitor-related bleeding risks.

Learning Objectives

  1. Review the scientific basis for benefit from P2Y12 inhibition as well as the bleeding risks that result from therapy and understand the known epidemiology of clinically significant bleeding complications with these agents
  2. Analyze and understand the different perspectives of various specialists on the chronic use of P2Y12 inhibitor therapy
  3. Review current management strategies for P2Y12 inhibitor-associated bleeding risks, as well as therapies still in development
  4. Review in detail the rationale and methodology of a phase 3 clinical trial that identifies patients suitable for ticagrelor reversal and follow its execution as the science of managing patients with ticagrelor-associated hemorrhage and procedural bleeding risk

Activity Description

Antiplatelet therapy is an essential part of secondary prevention of cardiovascular events.  In particular, dual antiplatelet therapy (DAPT)—the combination of aspirin with an oral P2Y12 receptor antagonist—is the predominant approach in patients with acute coronary syndromes (ACS), coronary-artery stenting, or previous myocardial infarction (MI). The three oral P2Y12 receptor antagonists that are in use are clopidogrel, prasugrel, and ticagrelor.

An unavoidable limitation of all three oral P2Y12 receptor antagonists is increased bleeding risk from platelet inhibition, which persists for several days after drug cessation. Establishment of hemostasis can be challenging in patients with major bleeding, such as intracranial or gastrointestinal hemorrhage. In addition, urgent invasive procedures, especially emergency procedures, are associated with an increased risk of periprocedural bleeding. If an emergency procedure is indicated, the surgeon or proceduralist must proceed while accepting the increased bleeding risk, often after empirically providing platelet transfusions, despite the ineffectiveness of such transfusions in reversing the antiplatelet effects of P2Y12 inhibitors. If an urgent procedure is indicated, the proceduralist must either proceed while anticipating the increased bleeding risk or postpone the procedure for several days while accepting the risks associated with delaying a clinically indicated procedure. American College of Cardiology Foundation–American Heart Association, European Society of Cardiology, and other society guidelines recommend cessation of oral P2Y12 receptor antagonists at least 3 to 7 days before surgery.  Currently, no reversal agents for P2Y12 receptor antagonists are known. Unlike the other P2Y12 receptor antagonists, ticagrelor is a reversible inhibitor, which makes the development of a specific reversal agent for ticagrelor feasible.

In this program Drs. Pollack and Bhatt discuss the clinical need for a reversal agent for antiplatelet therapy, as well as an ongoing trial of the first such drug.  They also comment on the difficulties faced by today’s clinical researchers during the ongoing COVID-19 pandemic.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding managing hemorrhagic complications and bleeding risks associated with platelet P2Y12 inhibitor therapy.

Agenda

  1. Inhibiting the Platelet P2Y12 Receptor: Efficacy and Safety
  2. Clinical Perspectives on Bleeding, Bleeding Risk, and Its Management in P2Y12 Inhibition
  3. Rationale and Methodology of a Phase 3 Placebo-Controlled Trial of a Specific Reversal Agent for a P2Y12 Inhibitor
  4. Challenges in Executing Clinical Trials in the Acute Care Environment

Course Chair

Charles V. Pollack Jr., MA, MD
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi

Faculty

Deepak L. Bhatt, MD, MPH
Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart & Vascular Center
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack Jr., MA, MD (Course Chair)
Grant/Research Support: AstraZeneca Pharmaceuticals; PROVEPHARM INC.
Consultant/Advisor: AstraZeneca Pharmaceuticals

Deepak L. Bhatt, MD, MPH
Grant/Research Support: Abbott; Afimmune Limited; Amarin Corporation; Amgen Inc.; AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim International GmbH; Bristol Myers Squibb Company; Cardax, Inc.; Chiesi USA, Inc.; CSL Behring; Eli Lilly and Company; Eisai Co., Ltd.; Ethicon Inc.; Ferring Pharmaceuticals; Forest Laboratories; Fractyl Laboratories, Inc.; Idorsia Pharmaceuticals Ltd; Ironwood Pharmaceuticals, Inc.; Ischemix; Lexicon; Medtronic; Pfizer Inc.; PhaseBio Pharmaceuticals; PLx Pharma Inc.; Regeneron Pharmaceuticals Inc.; Roche; Sanofi; Synaptic; The Medicines Company

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour, including 1.0 Pharmacotherapeutic Contact Hour (Provider Number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (JA4008190-0000-20-020-H04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
    CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    CME and CNE credit will be issued appropriate certificate of completion.
    Others may request a "certificate of completion".
  6. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from PhaseBio Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and PhaseBio Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: December 2, 2020
Expires: December 1, 2021
60 minutes to complete

Accredited By

Target Audience

Interventional and clinical cardiologists, cardiothoracic and trauma surgeons, and emergency medicine/critical care specialists, as well as other clinicians, including nurses, NPs, PAs, and pharmacists who manage patients with P2Y12 inhibitor-related bleeding risks.

Learning Objectives

  1. Review the scientific basis for benefit from P2Y12 inhibition as well as the bleeding risks that result from therapy and understand the known epidemiology of clinically significant bleeding complications with these agents
  2. Analyze and understand the different perspectives of various specialists on the chronic use of P2Y12 inhibitor therapy
  3. Review current management strategies for P2Y12 inhibitor-associated bleeding risks, as well as therapies still in development
  4. Review in detail the rationale and methodology of a phase 3 clinical trial that identifies patients suitable for ticagrelor reversal and follow its execution as the science of managing patients with ticagrelor-associated hemorrhage and procedural bleeding risk

Activity Description

Antiplatelet therapy is an essential part of secondary prevention of cardiovascular events.  In particular, dual antiplatelet therapy (DAPT)—the combination of aspirin with an oral P2Y12 receptor antagonist—is the predominant approach in patients with acute coronary syndromes (ACS), coronary-artery stenting, or previous myocardial infarction (MI). The three oral P2Y12 receptor antagonists that are in use are clopidogrel, prasugrel, and ticagrelor.

An unavoidable limitation of all three oral P2Y12 receptor antagonists is increased bleeding risk from platelet inhibition, which persists for several days after drug cessation. Establishment of hemostasis can be challenging in patients with major bleeding, such as intracranial or gastrointestinal hemorrhage. In addition, urgent invasive procedures, especially emergency procedures, are associated with an increased risk of periprocedural bleeding. If an emergency procedure is indicated, the surgeon or proceduralist must proceed while accepting the increased bleeding risk, often after empirically providing platelet transfusions, despite the ineffectiveness of such transfusions in reversing the antiplatelet effects of P2Y12 inhibitors. If an urgent procedure is indicated, the proceduralist must either proceed while anticipating the increased bleeding risk or postpone the procedure for several days while accepting the risks associated with delaying a clinically indicated procedure. American College of Cardiology Foundation–American Heart Association, European Society of Cardiology, and other society guidelines recommend cessation of oral P2Y12 receptor antagonists at least 3 to 7 days before surgery.  Currently, no reversal agents for P2Y12 receptor antagonists are known. Unlike the other P2Y12 receptor antagonists, ticagrelor is a reversible inhibitor, which makes the development of a specific reversal agent for ticagrelor feasible.

In this program Drs. Pollack and Bhatt discuss the clinical need for a reversal agent for antiplatelet therapy, as well as an ongoing trial of the first such drug.  They also comment on the difficulties faced by today’s clinical researchers during the ongoing COVID-19 pandemic.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding managing hemorrhagic complications and bleeding risks associated with platelet P2Y12 inhibitor therapy.

Agenda

  1. Inhibiting the Platelet P2Y12 Receptor: Efficacy and Safety
  2. Clinical Perspectives on Bleeding, Bleeding Risk, and Its Management in P2Y12 Inhibition
  3. Rationale and Methodology of a Phase 3 Placebo-Controlled Trial of a Specific Reversal Agent for a P2Y12 Inhibitor
  4. Challenges in Executing Clinical Trials in the Acute Care Environment

Course Chair

Charles V. Pollack Jr., MA, MD
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi

Faculty

Deepak L. Bhatt, MD, MPH
Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart & Vascular Center
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack Jr., MA, MD (Course Chair)
Grant/Research Support: AstraZeneca Pharmaceuticals; PROVEPHARM INC.
Consultant/Advisor: AstraZeneca Pharmaceuticals

Deepak L. Bhatt, MD, MPH
Grant/Research Support: Abbott; Afimmune Limited; Amarin Corporation; Amgen Inc.; AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim International GmbH; Bristol Myers Squibb Company; Cardax, Inc.; Chiesi USA, Inc.; CSL Behring; Eli Lilly and Company; Eisai Co., Ltd.; Ethicon Inc.; Ferring Pharmaceuticals; Forest Laboratories; Fractyl Laboratories, Inc.; Idorsia Pharmaceuticals Ltd; Ironwood Pharmaceuticals, Inc.; Ischemix; Lexicon; Medtronic; Pfizer Inc.; PhaseBio Pharmaceuticals; PLx Pharma Inc.; Regeneron Pharmaceuticals Inc.; Roche; Sanofi; Synaptic; The Medicines Company

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour, including 1.0 Pharmacotherapeutic Contact Hour (Provider Number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (JA4008190-0000-20-020-H04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
    CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    CME and CNE credit will be issued appropriate certificate of completion.
    Others may request a "certificate of completion".
  6. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from PhaseBio Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and PhaseBio Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.